Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: https://twitter.com/VanessaWelten.
Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Hematol Oncol Clin North Am. 2022 Jun;36(3):569-582. doi: 10.1016/j.hoc.2022.02.008. Epub 2022 May 13.
Colorectal cancer with peritoneal involvement is traditionally recognized as having a poor prognosis, with treatment initially limited to palliative systemic chemotherapy alone. The introduction of cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy drastically altered the course of this disease entity and has demonstrated improvements in survival outcomes. Recent evidence has shown benefit of CRS but did not show benefit of HIPEC. Under the guidance of a multidisciplinary team and for appropriately selected patients, CRS is a key component of treatment that can positively alter the course of disease outcomes for patients with peritoneal involvement.
结直肠癌伴腹膜转移传统上被认为预后不良，初始治疗仅限于姑息性全身化疗。细胞减灭术（CRS）联合腹腔热灌注化疗（HIPEC）的引入极大地改变了这一疾病实体的进程，并显示出在生存结果方面的改善。最近的证据表明 CRS 有益，但 HIPEC 无益。在多学科团队的指导下，对于选择合适的患者，CRS 是治疗的关键组成部分，可以积极改变腹膜转移患者的疾病结局。
